The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding
Abstract
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. In this paper, we describe the development and mechanism of action of type III inhibitors that bind CDK2 with nanomolar affinity. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as contraceptive agents is seen by incubation with spermatocyte chromosome spreads from mouse testicular explants, where they recapitulate Cdk2 -/- and Spdya -/- phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, a recent study shows that by exploiting the long-range communication between ATP and cyclin binding sites, it is possible to design selective cyclin-dependent kinase 2 (Cdk2) inhibitors [52].”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [52]
In the citing paper
“Previous studies have indicated that most ATP-competitive inhibitors of Cdk2 exhibit positive cooperativity with cyclin binding.”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [52]
In the citing paper
“In contrast, the newly developed selective Cdk2 inhibitors demonstrate negative cooperativity with cyclin, effectively preventing Cdk2 activation while maintaining a lower level of toxicity.”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00725-y · Cited by 65
Self-citation
Research works printed but not linked: 53
- Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2, 58–61 (2007). · DOI · Paper page
- Teng, M. et al. Development of CDK2 and CDK5 dual degrader TMX-2172. Angew. Chem. Int. Ed. Engl. 59, 13865–70 (2020). · DOI
- Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129–132 (2016). · DOI · Paper page
- To, C. et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Disco. 9, 926–43 (2019). · DOI · Paper page
- To, C. et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat. Cancer 3, 402–417 (2022). · DOI
- Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–76 (2014). · DOI · Paper page
- Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012). · DOI · Paper page
- Dummer, R. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19, 603–15 (2018). · DOI · Paper page
- Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharm. Res. 165, 105463 (2021). · DOI · Paper page
- Rea, D. et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138, 2031–41 (2021). · DOI · Paper page
- Pan, Y. & Mader, M. M. Principles of kinase allosteric inhibition and pocket validation. J. Med. Chem. 65, 5288–99 (2022). · DOI
- Laufkotter, O., Hu, H., Miljkovic, F. & Bajorath, J. Structure- and similarity-based survey of allosteric kinase inhibitors, activators, and closely related compounds. J. Med. Chem. 65, 922–34 (2022). · DOI
- Berthet, C., Aleem, E., Coppola, V., Tessarollo, L. & Kaldis, P. Cdk2 knockout mice are viable. Curr. Biol. 13, 1775–1785 (2003). · DOI · Paper page
- Ortega, S. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35, 25–31 (2003). · DOI · Paper page
- Faber, E. B., Wang, N. & Georg, G. I. Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception. Biol. Reprod. 103, 357–67 (2020). · DOI
- McGrath, D. A. et al. Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins. EMBO J. 36, 2251–62 (2017). · DOI
- Mikolcevic, P. et al. Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope. Nat. Commun. 7, 11084 (2016). · DOI
- Merrick, K. A. et al. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol. Cell 42, 624–636 (2011). · DOI
- Betzi, S. et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6, 492–501 (2011). · DOI · Paper page
- Faber, E. B. et al. Cooperativity between orthosteric inhibitors and allosteric inhibitor 8-anilino-1-naphthalene sulfonic acid (ANS) in cyclin-dependent kinase 2. ACS Chem. Biol. 15, 1759–64 (2020). · DOI
- Weber, G. & Young, L. B. Fragmentation of bovine serum albumin by pepsin: I. The origin of the acid expansion of the albumin molecule. J. Biol. Chem. 239, 1415–1423 (1964). · DOI · Paper page
- Stryer, L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites. J. Mol. Biol. 13, 482–495 (1965). · DOI · Paper page
- Laurence, D. J. Interactions of calf-thymus histone fractions in aqueous solution with 8-anilinonaphthalene-1-sulphonic acid. Biochem. J. 99, 419–426 (1966). · doi:10.1042/bj0990419
- Brand, L., Gohlke, J. R. & Rao, D. S. Evidence for binding of rose bengal and anilinonaphthalenesulfonates at the active site regions of liver alcohol dehydrogenase. Biochemistry 6, 3510–3518 (1967). · doi:10.1021/bi00863a024
- Schonbrunn, E., Eschenburg, S., Luger, K., Kabsch, W. & Amrhein, N. Structural basis for the interaction of the fluorescence probe 8-anilino-1-naphthalene sulfonate (ANS) with the antibiotic target MurA. Proc. Natl Acad. Sci. USA 97, 6345–6349 (2000). · DOI · Paper page
- Martin, M. P. et al. A novel approach to the discovery of small-molecule ligands of CDK2. Chembiochem 13, 2128–2136 (2012). · DOI
- Faber, E. B. et al. Screening through lead optimization of high affinity, allosteric cyclin-dependent kinase 2 (CDK2) inhibitors as male contraceptives that reduce sperm counts in mice. J. Med. Chem. 66, 1928–40 (2023). · DOI
- Nepali, K., Lee, H. Y. & Liou, J. P. Nitro-group-containing drugs. J. Med. Chem. 62, 2851–93 (2019). · DOI · Paper page
- Wood, D. J. et al. Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. Cell Chem. Biol. 26, 1–10 (2018).
- Kim, D. M., Yang, K. & Yang, B. S. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A. Exp. Mol. Med. 35, 421–430 (2003). · DOI
- Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013). · DOI · Paper page
- Schmidt, T. et al. ProteomicsDB. Nucleic Acids Res. 46, D1271–D1281 (2018). · DOI · Paper page
- Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021). · DOI · Paper page
- Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344–2353 (2010). · DOI · Paper page
- Roskoski, R. Jr Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharm. Res. 107, 249–75 (2016). · DOI · Paper page
- Au-Yeung, G. et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin. Cancer Res. 23, 1862–74 (2017). · DOI
- Viera, A. et al. CDK2 is required for proper homologous pairing, recombination and sex-body formation during male mouse meiosis. J. Cell Sci. 122, 2149–2159 (2009). Pt 12. · DOI
- Tu, Z. et al. Speedy A-Cdk2 binding mediates initial telomere-nuclear envelope attachment during meiotic prophase I independent of Cdk2 activation. Proc. Natl Acad. Sci. USA 114, 592–597 (2017). · DOI
- Kalra, S., Joshi, G., Munshi, A. & Kumar, R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur. J. Med. Chem. 142, 424–58 (2017). · DOI
- Merrick, K. A. et al. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol. Cell 32, 662–672 (2008). · DOI · Paper page
- Zhang, J. et al. Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells. Nat. Commun. 13, 2835 (2022). · DOI
- Pauli, G. F. et al. Importance of purity evaluation and the potential of quantitative (1)H NMR as a purity assay. J. Med. Chem. 57, 9220–9231 (2014). · DOI · Paper page
- Pauli, G. F. et al. Correction to Importance of Purity Evaluation and the Potential of Quantitative 1H NMR as a Purity Assay. J. Med. Chem. 58, 9061–9061 (2015). · doi:10.1021/acs.jmedchem.5b01667
- Schonbrunn, E. et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J. Med. Chem. 56, 3768–3782 (2013). · DOI
- Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D. Biol. Crystallogr. 66, 133–144 (2010). Pt 2. · DOI · Paper page
- McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658–674 (2007). Pt 4. · DOI · Paper page
- Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. D. Biol. Crystallogr. 65, 1074–1080 (2009). Pt 10. · DOI · Paper page
- Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2010). Pt 2. · DOI · Paper page
- Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–2132 (2004). Pt 12 Pt 1. · DOI · Paper page
- Wiseman, T., Williston, S., Brandts, J. F. & Lin, L.-N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179, 131–137 (1989). · DOI · Paper page
- Schaaf, T. M. et al. High-throughput spectral and lifetime-based FRET screening in living cells to identify small-molecule effectors of SERCA. SLAS Disco. 22, 262–73 (2017). · DOI
- Jafari, R. et al.The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122 (2014). · DOI · Paper page
- Chen, Y. et al. The SUN1-SPDYA interaction plays an essential role in meiosis prophase I. Nat. Commun. 12, 3176 (2021). · DOI
Cited by
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Olivieri, C., Wu, J., Taylor, S. S., & Veglia, G. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103169 · Cited by 1
Metadata
- Authors
- Faber, E. B., Sun, L., Tang, J., Roberts, E., Ganeshkumar, S., Wang, N., Rasmussen, D., Majumdar, A., Hirsch, L. E., John, K., Yang, A., Khalid, H., Hawkinson, J. E., Levinson, N. M., Chennathukuzhi, V., Harki, D. A., Schönbrunn, E., & Georg, G. I.
- ORCID
- Venue
- Nature Communications
- Published
- 2023-06-03
- Volume
- 14
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 54
- References
- 1
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R61 HD099743, HHSN27520180007I, R01 HD080431)
- Minnesota Ovarian Cancer Alliance (NA)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008244, T32 GM132029, R01 GM121515)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30 CA232303)
- National Institute for General Medical Sciences
- U.S. Department of Defense (W81XWH-19-1-0336, W81XWH-21-1-0674)
- Fulbright Association (NA)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. https://app.cochat.ai/papers/10.1038/s41467-023-38732-x
- The paper
- Faber, E. B., Sun, L., Tang, J., Roberts, E., Ganeshkumar, S., Wang, N., Rasmussen, D., Majumdar, A., Hirsch, L. E., John, K., Yang, A., Khalid, H., Hawkinson, J. E., Levinson, N. M., Chennathukuzhi, V., Harki, D. A., Schönbrunn, E., & Georg, G. I. (2023). Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. Nature Communications. https://doi.org/10.1038/s41467-023-38732-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.